Status:
UNKNOWN
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Lead Sponsor:
Jordan Feld
Collaborating Sponsors:
University Health Network, Toronto
Conditions:
Lung Transplant Infection
Heart Transplant Infection
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The success of transplantation is significantly hindered by the lack of sufficient number of available donors. Many potential donor organs cannot be utilized in clinical transplantation because donors...
Detailed Description
The investigators aim to transplant 40 recipients with end-stage organ disease (20 lung, and 20 other organs) using organs from HCV+ donors. Lungs to be used for transplantation will be exposed to ex ...
Eligibility Criteria
Inclusion
- Donor
- Age \<70
- NAT+ HCV donor
- Donor
Exclusion
- HIV positive or HTLV 1/2 positive
- Hepatitis B surface Antigen positive
- Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc)
- Age\>70
- Recipient Inclusion Criteria:
- Recipients listed for kidney, kidney-pancreas, pancreas transplant alone, heart, or lung transplant
- HCV NAT negative
- Provides written informed consent
- Recipient
Key Trial Info
Start Date :
August 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04017338
Start Date
August 6 2018
End Date
December 31 2024
Last Update
July 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2